

# Clindamycin vs TMP/SMX vs Incision & Drainage alone for Small Skin Abscesses<sup>1</sup>

A placebo-controlled trial of antibiotics for smaller skin abscesses

## BOTTOM LINE:

- Compared to placebo, outpatients with a single small *S.aureus* (~50% MRSA) skin abscess who underwent incision & drainage & received an antibiotic clindamycin or TMP/SMX, were more likely to have clinical cure by test-of-cure visit (i.e. 7 to 10 days after treatment ended) NNT=7-8. The difference between clindamycin and TMP/SMX was non-statically significant.
  - Only 6.9% (13/188) of the participants *S.aureus* isolates were resistant to clindamycin, which is less than current SK rates.
- Individuals who were treated with clindamycin were more likely to have treatment-associated adverse events. There were no reported cases of *C. difficile*.
  - note: the study was conducted at 6 sites over a 6 year period; impact on antimicrobial resistance was not reported
- Overall, the trial supports the use of clindamycin or TMP/SMX in areas with a MRSA of ~50% and good *S.aureus* susceptibility to these antibiotics. However, I&D is most important & an antibiotic only made a difference in 1/7 to 1/8 patients versus placebo.

## BACKGROUND

- Clinical practice guidelines/ references recommend incision & drainage (I&D) for abscesses, & note that the procedure alone is often all that is required for uncomplicated abscesses.<sup>2,3,4</sup>
- A small 2014 meta-analysis (4 RCTs, N=589) found no difference in clinical cure rates 7 to 10 days after treatment when (I&D) + antibiotics (cephalosporin or TMP/SMX) was compared to I&D alone for uncomplicated abscesses.<sup>5</sup>
- In 2016, a larger RCT (n=1,265) compared high-dose TMP/SMX (2 double-strength tablets BID) + I&D to I&D alone in outpatients presenting to the ER with uncomplicated abscesses. TMP/SMX had a higher rate of clinical cure 1 to 2 weeks after treatment ended (NNT=14), but also a higher discontinuation rate & more adverse events.<sup>6</sup>

## TRIAL BACKGROUND

**DESIGN:** randomized, double-blind, placebo-controlled multicentre 6 U.S. sites ITT/PPA trial with concealed allocation. Enrollment May 2009 to January 2015. Funding: National Institute of Allergy & Infectious Diseases of the National Institutes of Health.

**INTERVENTION:** incision & drainage of abscess AND

- clindamycin 300mg po TID x 10 days (pediatric dose: 25-30mg/kg/day), or
- TMP/SMX 160mg/800mg po BID (i.e. 1 double strength tablet twice daily) x 10 days (pediatric dose: 8-10mg TMP/kg/day), or
- placebo

**INCLUSION:** outpatients with a single abscess (≤5cm, or ≤4cm for participants 1-8 yrs old, or ≤3cm if 6-11months old) with ≥2 of the following signs or symptoms for ≥24hrs: erythema, swelling or induration, local warmth, purulent drainage, and tenderness to pain or palpation.

**EXCLUSION:** superficial skin infections (e.g. impetigo), infection at a body site requiring specialized management (e.g. perirectal, genital, or hand infection), human or animal bite, oral temperature >38.5° (or >38° for children 6-11 months old), presence of systemic inflammatory response syndrome criteria, immunosuppressive therapy or an immunocompromising condition (e.g. DM, CKD), BMI >40kg/m<sup>2</sup>, surgical site or prosthetic device infection, systemic antistaphylococcal antibacterial therapy in the previous 14 days; & required hospitalization, LTC resident, cancer, inflammatory disorder or major surgery in the past 12 months.

**POPULATION** at baseline: n=786

- adults 64.2%, children 35.8% (~21% 1-8yrs, 12.5% 9-17yrs, 2.2% <1yr), mean age 25.5 years
- ♂ 57%, Black / African American ~62%, Caucasian ~30%
- body temperature 36.6°±0.47°, area of wound 3.89cm<sup>2</sup>±4.3cm<sup>2</sup>, area of surrounding erythema 27.44cm<sup>2</sup>±86.82cm<sup>2</sup>
- culture obtained 99.4%, positive culture results 91.3%, *Staph aureus* isolated 67% (MRSA 49.4%), coagulase-negative staphylococcus 13.2%, Streptococcus species 6.9%, other 15%

## RESULTS

TABLE: EFFICACY & SAFETY

CLINICAL ENDPOINTS	CLINDAMYCIN 300MG PO TID	TMP/SMX 1 DS BID	PLACEBO	ARR/ARI			NNT/NNH /10 DAYS		
				Clinda vs TMP/SMX	Clinda vs Placebo	TMP/SMX vs Placebo	Clinda vs TMP/SMX	Clinda vs Placebo	TMP/SMX vs Placebo
<b>PRIMARY ENDPOINT: CLINICAL CURE BY TEST-OF-CURE VISIT (i.e. 7 to 10 days after the end of treatment)</b>									
Intention-to-treat population	83.1% (221/266)	81.7% (215/263)	68.9% (177/257)	NS	14.2%	12.8%	-	7	8
Population that could be evaluated †	92.9% (221/238)	92.7% (215/232)	80.5% (177/220)		12.4%	12.2%		9	9
<b>SECONDARY ENDPOINTS (ITT Analysis; results were similar for the population that could be evaluated)</b>									
Cure rate at 1 month follow-up	78.6% (209/266)	73% (192/263)	62.6% (161/257)	NS	16%	10.4%	-	7	10
Cure rate in <i>S.aureus</i> infections	83.5% (157/188)	83.2% (149/179)	63.8% (102/160)		19.7%	19.4%		6	6
Cure rate in MRSA infections	81.7% (116/142)	84.6% (110/130)	62.9% (73/116)		18.8%	21.7%		6	5
Cure rate in MSSA infections	89.1% (41/46)	79.6% (39/49)	65.9% (29/44)		23.2%	NS		5	-
Cure rate in non- <i>S.aureus</i> infxns	83.8% (57/68)	81.9% (59/72)	83.1% (69/83)		NS	NS		-	-
<b>ADDITIONAL ANALYSES (population that could be evaluated, or took ≥1 study doses)</b>									
New or recurrent infection at 1 month follow-up	6.8% (15/221)	13.5% (29/215)	12.4% (22/177)	6.7%	NS	NS	15	-	-
Treatment-associated adverse events	21.9% (58/265)	11.1% (29/261)	12.5% (32/255)	10.8%	9.4%	1.4%	p-values & CI not reported for AE no cases of <i>C. difficile</i> reported		
Diarrhea	16.2% (43/265)	5.4% (14/261)	6.7% (17/255)	10.8%	9.5%	1.3%			

† Participants who received treatment or placebo & completed the end-of-treatment and test-of-cure visits.

*S.aureus* isolates resistant to clindamycin 4.9% (n=13/266)

**Age groups:** for the population that could be evaluated, children had a higher cure rate with clindamycin than with TMP/SMX or placebo (versus adults, p<0.04). This outcome was non-statistically significant for the ITT analysis.

**STRENGTHS, LIMITATIONS, & UNCERTAINTIES**

- STRENGTHS:**
- Study protocol included a standardized incision & drainage procedure.
  - Funded by the National Institute of Allergy & Infectious Diseases of the National Institutes of Health.
  - Investigators were blinded to C&S results.
  - Intention-to-treat analysis with a “population that could be evaluated” analysis. For the latter, adherence was assessed by self-report and drug accountability for participants who returned blister packs / suspension bottles.
  - Primary endpoint was assessed 7 to 10 days after treatment ended (i.e. 17 to 20 days after I&D).
  - Subgroup analysis based on culture results.
  - Duration of therapy was reported for non-adherent patients (in supplement).
- LIMITATIONS:**
- Less than half (43.6%) of participants were fully adherent to the study regimen (majority of the non-adherent patient population took 76-99% of the doses).
  - p-values & confidence intervals were not published for the safety analysis.
  - Subgroup analyses were underpowered, and therefore can only be hypothesis generating.
- UNCERTAINTIES:**
- Efficacy of doxycycline in comparison to clindamycin or TMP/SMX.
  - Efficacy of shorter courses of antibiotics (i.e. ≤1 week).
  - Ideal dose of TMP/SMX (individuals with a BMI >40kg/m<sup>2</sup> were excluded).
  - For new or recurrent infections at the 1 month follow-up, the difference between clindamycin vs TMP/SMX was statistically significant (in favour of clindamycin) but the difference between clindamycin vs placebo was non-statistically significant (p=0.06) [see Results Table on first page]. As noted above, all secondary endpoints were underpowered. Query if the difference between clindamycin vs TMP/SMX was a chance finding.

**RxFILES RELATED LINKS**

- **RxFiles Skin & Soft Tissue Infection Chart:** <http://www.rxfiles.ca/rxfiles/uploads/documents/members/ABX-Skin-Infections.pdf>
- **RxFiles Trial Summary TMP/SMX vs Placebo for uncomplicated skin abscesses:** [http://www.rxfiles.ca/rxfiles/uploads/documents/TMP\\_SMX%20vs%20Placebo%20for%20Uncomplicated%20Skin%20Abscess\\_Trial\\_Summary.pdf](http://www.rxfiles.ca/rxfiles/uploads/documents/TMP_SMX%20vs%20Placebo%20for%20Uncomplicated%20Skin%20Abscess_Trial_Summary.pdf)
- **RxFiles Trial Summary Clindamycin versus TMP/SMX for uncomplicated skin infections:** <http://www.rxfiles.ca/rxfiles/uploads/documents/Trial%20Summary%20TMP-SMX%20vs%20Clindamycin%20in%20Uncomp%20SSTI.pdf>

♂=male AE=adverse events ARI=absolute risk increase ARR=absolute risk reduction BID=twice daily BMI=body mass index C&S=culture & sensitivity CKD=chronic kidney disease DM=diabetes mellitus DS=double strength ER=Emergency Room I&D=incision & drainage LTC=long-term care MRSA=methicillin-resistant *Staphylococcus aureus* MSSA=methicillin-susceptible *Staphylococcus aureus* N/n=number NNH=number needed to harm NNT=number needed to treat NS=non-statistically significant PPA=Per-protocol analysis RCT=randomized controlled trial SK=Saskatchewan TMP/SMX=trimethoprim/sulfamethoxazole

**ACKNOWLEDGEMENTS: Contributors & Reviews:** Loren Regier, Justin Kosar, Dr. Tessa Laubscher, Brent Jensen, Caitlin Coons **Prepared By:** Lynette Kosar

**DISCLAIMER:** The content of this newsletter represents the research, experience and opinions of the authors and not those of the Board or Administration of Saskatoon Health Region (SHR). Neither the authors nor Saskatoon Health Region nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the newsletter will imply acknowledgment of this disclaimer and release any responsibility of SHR, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources. Additional information and references online at [www.RxFiles.ca](http://www.RxFiles.ca) **Copyright 2017 – RxFiles, Saskatoon Health Region (SHR)**

**References:**

1. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, et al; DMID 07-0051 Team. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. *N Engl J Med.* 2017 Jun 29;376(26):2545-2555. PubMed PMID: 28657870.
2. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, et al; Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2014 Jul 15;59(2):e10- 52.
3. Bugs & Drugs 2012.
4. Anti-infective Review Panel. Anti-infective guidelines for community-acquired infections. Toronto: MUMS Guideline Clearinghouse; 2013.
5. Singer AJ, and Thode HC Jr. Systemic antibiotics after incision and drainage of simple abscesses: a meta-analysis. *Emerg Med J.*
6. Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. *N Engl J Med.* 2016 Mar 3;374(9):823-32.